A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene

Protocol Number
AG-221-AML-004

To Learn More Call
201-510-0910

Phase 2, safety and efficacy study of isatuximab, an anti-CD38 monoclonal antibody, administered by intravenous infusion in patients with relapsed or refractory T-acute lymphoblastic leukemia or T-lymphoblastic lymphoma

Sponsor
Sanofi Aventis

Protocol Number
ACT14596

To Learn More Call
201-510-0910

A Phase 1, Multicenter, Open-Label, Safety Study of AG-120 or AG-221 in Combination with Induction Therapy and Consolidation Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 and/or IDH2

Sponsor
Agios

Protocol Number
AG120-221-C-001

To Learn More Call
201-510-0910

A Phase 1, Open-label, Adaptive Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Anti-tumor Activity of ADCT-402 in Patients with Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
ADC Therapeutics

Protocol Number
ADCT-402-102-ALL

To Learn More Call
201-510-0910

An observational study of patients with relapsed or refractory Ph-negative acute lymphoblastic leukemia in the US –Site Interest Inquiry Pending

Sponsor
Amgen

Protocol Number
20150253

To Learn More Call
201-510-0910

A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients with Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Ariad

Protocol Number
AP24534-14203

To Learn More Call
201-510-0910

A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) versus Treatment Choice in Adults with Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated with Hypomethylating Agents

Sponsor
Astex

Protocol Number
SGI-110-07

To Learn More Call
201-510-0910

A Phase 3 Open-label, Multicenter, Randomized Study of ASP2215 versus Salvage Chemotherapy in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) with FLT3 Mutation Protocol for Phase 3 Study of ASP2215

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Astellas

Protocol Number
2215-CL-0301

To Learn More Call
201-510-0910

Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry

Sponsor
Celgene

Protocol Number
Connect MDS and AML

To Learn More Call
201-510-0910

A PHASE 3, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY COMPARING THE EFFICACY AND SAFETY OF AG 221 (CC-90007) VERSUS CONVENTIONAL CARE REGIMENS IN OLDER SUBJECTS WITH LATE STAGE ACUTE MYELOID LEUKEMIA HARBORING AN ISOCITRATE DEHYDROGENASE 2 MUTATION

Type of Cancer
Leukemia

Site
Hackensack

Sponsor
Celgene